科美诊断(688468) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 111,390,688.04, representing a year-on-year increase of 10.36%[5] - The net profit attributable to shareholders for the same period was CNY 38,392,507.40, reflecting a growth of 10.21% compared to the previous year[5] - Total operating revenue for Q1 2024 reached ¥111,390,688.04, an increase of 10.9% compared to ¥100,933,657.63 in Q1 2023[25] - Net profit for Q1 2024 was ¥38,392,507.40, representing a 10.5% increase from ¥34,836,760.84 in Q1 2023[26] - The total comprehensive income attributable to the parent company was CNY 38,392,507.40, compared to CNY 34,836,760.84 in Q1 2023, reflecting an increase of 7.9%[27] Cash Flow - The net cash flow from operating activities increased significantly by 106.70%, amounting to CNY 37,767,684.23, primarily due to increased sales collections[6] - In Q1 2024, the company reported a net cash flow from operating activities of CNY 37,767,684.23, a significant increase of 106.5% compared to CNY 18,271,622.63 in Q1 2023[29] - The net cash flow from investing activities was CNY 60,935,030.35, a turnaround from a negative cash flow of CNY -120,379,638.70 in Q1 2023[29] - Cash and cash equivalents at the end of Q1 2024 totaled CNY 277,035,240.30, an increase from CNY 197,051,012.53 at the end of Q1 2023[29] - The company’s cash flow from financing activities showed a net outflow of CNY -23,274,506.27, contrasting with a net inflow of CNY 7,081,853.95 in Q1 2023[29] Research and Development - Research and development expenses totaled CNY 20,095,592.77, which is a decrease of 6.86% year-on-year, and accounted for 18.04% of operating revenue, down by 3.34 percentage points[6] - Research and development expenses for Q1 2024 amounted to ¥18,615,108.51, compared to ¥17,088,512.72 in Q1 2023, indicating a growth of 8.9%[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,044[9] - The largest shareholder, Ningbo Free Trade Zone Yingweili Enterprise Management Partnership, held 26.93% of the shares, totaling 108,000,008 shares[10] - The top ten shareholders include significant entities such as Shanghai Peixi Investment Management Partnership and Ningbo Kebo Ao, with the largest shareholder holding 25,731,070 shares[13] - The company has not identified any other relationships or concerted actions among the remaining circulating shareholders[13] - The company has not engaged in any securities lending or borrowing activities among the top ten shareholders[14] Asset and Liability Overview - The total assets at the end of the reporting period were CNY 1,819,304,508.30, showing a slight decrease of 0.07% from the end of the previous year[6] - Current assets totaled ¥1,048,954,556.06, a decrease of 4.9% from ¥1,102,627,338.36 at the end of 2023[22] - Total liabilities amounted to ¥435,928,828.16, a slight increase from ¥431,760,797.88 in the previous period[23] - The company maintained a stable equity position with total equity at ¥1,383,375,680.14, slightly down from ¥1,388,801,768.59[23] Share Repurchase - As of March 31, 2024, the company has repurchased a total of 5,574,913 shares, accounting for 1.39% of the total share capital of 401,108,000 shares[15] - The total amount paid for the repurchased shares is RMB 44,650,529, with a maximum price of RMB 10.30 per share and a minimum price of RMB 5.83 per share[16] - The company plans to use between RMB 30 million and RMB 60 million for share repurchase, with a maximum repurchase price of RMB 16.68 per share[14] Other Financial Metrics - The weighted average return on equity increased by 0.28 percentage points to 2.77%[5] - The basic and diluted earnings per share for the quarter were both CNY 0.10, an increase of 11.11% year-on-year[5] - The company reported non-recurring gains of CNY 3,605,146.48 for the period, primarily from fair value changes of financial assets[8]